Clinical trial
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell…
NCT00416351 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00416351 |
|---|---|
| Title | Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment |
| Official title | A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH University of Rochester The Cleveland Clinic |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Small Intestine Cancer |
| Intervention type | Drug |
| Interventions | clofarabine |
| Enrollment | 29 |
| Start date | Jun 27, 2006 |
| Primary completion | Mar 1, 2021 |
| Completion | Mar 1, 2021 |
| First posted | Dec 28, 2006 |
| Last update posted | May 17, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: